Author: Irene

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - On the evening of 30 March, Fosun International announced its 2025 annual results. During the Reporting Period, the Group’s total revenue reached RMB173.43 billion, and adjusted industrial operation profit was RMB4 billion.Compared to prior years, Fosun’s results have remained solid. However, pursuant to the principle of prudence, Fosun made one-off non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments, resulting in a book loss of RMB23.4 billion in 2025, of which real estate-related impairment accounted for approximately 55%, while impairment of non-core assets accounted for approximately 45%.Fosun emphasized in the announcement that these provisions do not affect the Company’s overall operations and cash flow. However, Guo Guangchang, Chairman of Fosun International, offered a sincere apology in this year’s Letter to Shareholders, stating that “A loss is never desirable.” He further explained that, “Under the current market conditions, some of the projects we invested in years ago are now valued differently from what we expected at the time of investment. Accordingly, the Board has taken a prudent decision to complete this asset impairment, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas. At a time when the global economy is generating opportunities amid volatility and China’s innovation-driven industries are gaining growth momentum, deepening our strategic focus now allows us to optimize our asset structure and helps us secure a stronger position in key sectors, positioning Fosun as a leaner, healthier, and more sustainable company.”In recent years, Fosun has steadily advance its strategy of “streamlining operations and strengthening the business, focusing on core businesses”, generating approximately RMB75 billion in cash returns from asset and business divestments. This round of impairments marks Fosun’s decisive step to clear accumulated risks on a one-off basis and shed “historical burdens”. While the book loss appears significant, from the capital market’s perspective, Fosun’s share price has rebounded more than 10% since the announcement of its results preview on 6 March, indicating the market has recognized and accepted its “risk clearance”.In his Letter to Shareholders, Guo Guangchang described this asset impairment as “repairing the roof on a sunny day”. Fosun International’s results announcement offers a clear illustration. Fosun’s core businesses has continued to deliver steady profits, reflecting solid operating fundamentals. At the same time, its long-established innovation and globalization strategies have become the core growth drivers for the Company. Collectively, these achievements underpin Fosun’s confidence in proceeding with “risk clearance” at this stage.Business fundamentals remain solid, pharmaceuticals and insurance segments deliver strong resultsLet’s start with Fosun’s business fundamentals. In 2025, Fosun International’s four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group’s total revenue. This demonstrates the results of Fosun’s strategic adjustment of “focusing on core businesses”, effectively addressing prior market concerns over “diversification”.Among them, Fosun Pharma, a core subsidiary of Fosun, achieved a net profit attributable to shareholders of the parent of RMB3.371 billion in 2025, representing a year-on-year increase of 21.69%. Fosun Pharma’s biopharmaceutical innovation platform, Henlius, recorded revenue of RMB6.667 billion and net profit of RMB827 million, delivering growth in both revenue and net profit for the third consecutive year.Next, let’s take a look at Fosun’s most important overseas subsidiary, Fosun Insurance Portugal. In 2025, Fosun Insurance Portugal achieved strong growth in revenue and net profit. Its net profit attributable to owners of the parent amounted to EUR201 million, up 15.8% year-on-year, establishing it as a stable contributor to Fosun’s profitability. Fosun Insurance Portugal has benefited significantly from Fosun’s global ecosystem, expanding its presence from Portugal to overseas markets such as Europe, Latin America and Africa. In 2025, Fosun Insurance Portugal received its inaugural A rating from S&P Global, reflecting international recognition of its asset quality and risk resilience.In Chinese mainland, Fosun’s two insurance companies have also performed well. Pramerica Fosun Life Insurance’s premium income for the year reached RMB13.28 billion, up 41.6% year-on-year, while net profit surged over 492% to RMB650 million. Meanwhile, Fosun United Health Insurance recorded insurance income of RMB7.84 billion in 2025, representing a year-on-year increase of 50.1%, with net profit reaching RMB139 million, marking five consecutive years of profitability.Core drivers: innovation and globalization strategiesFosun Pharma and Fosun Insurance Portugal embody Fosun’s two core strategies: innovation and globalization.Since its establishment, Fosun has always regarded “innovation-driven research and development (R&D)” as its core strategy, and began its global expansion following its listing in Hong Kong. After years of intensive investment and exploration, innovation and globalization strategies have become the core driving forces behind Fosun’s development, consistently delivering results that generate “compounding returns” over time.The biggest change for Fosun Pharma in 2025 was strong growth in its innovative drug breakthroughs. During the Reporting Period, Fosun Pharma’s revenue from innovative drugs reached RMB9.893 billion, representing a year-on-year increase of 29.59%, accounting for 33.16% of its pharmaceutical business revenue. Fosun Pharma had 16 indications of its 7 innovative drugs approved for marketing in China and overseas markets, while marketing applications for 6 innovative drug candidates were accepted.During the Reporting Period, nearly 40 of Fosun’s innovative drug clinical trials were approved by regulatory authorities in China, the United States and Europe, while multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth.Henlius’ HLX43 remains the main focus of market interest. As a PD-L1-targeted antibody drug conjugate (ADC) with potential best-in-class characteristics and broad anti-tumor activity across multiple tumor types, HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, esophageal squamous cell carcinoma (ESCC), and other indications. On 27 January 2025, it was approved for clinical trials in Chinese mainland, positioning it to become another landmark product for Fosun.This year, Fosun’s international business development (BD) efforts for innovative drugs made a notable impression on the market. For example, at the beginning of 2026, Fosun Pharma entered into an agreement with Eisai Co., Ltd. in relation to HANSIZHUANG, with a potential total value of over USD300 million. At the end of 2025, Fosun Pharma’s subsidiary, Yao Pharma, signed a global exclusive licensing agreement with Pfizer, with a potential total value of over USD2 billion; Fosun Pharma Industrial entered into a strategic collaboration with biotechnology company Clavis Bio, with Fosun Pharma eligible to receive up to USD7.25 billion in payments.In terms of globalization, Fosun has established a profound business presence in more than 40 countries and regions worldwide. Today, it has achieved comprehensive globalization across products, services, and brands. In 2025, Fosun’s overseas revenue reached RMB94.86 billion, accounting for 54.7% of total revenue, representing a year-on-year increase of 5.4 percentage points. Fosun’s globalization strategy has evolved from “acquiring globally” to “earning globally”.Club Med, a subsidiary of Fosun Tourism Group, operates 67 resorts worldwide. During the Reporting Period, Club Med once again achieved record-high performance, with revenue reaching RMB18.07 billion, representing a year-on-year increase of 3.6%, while operating profit reached RMB1.44 billion, up 4.6% from 2024.Hainan Mining, a subsidiary of Fosun, has now developed into a global resource + new energy company and has made remarkable strides in its global expansion. Hainan Mining’s model of “overseas resources + processing in Hainan” entered a substantive operational stage in 2025. Its Bougouni Lithium Mine in Mali produced 45,000 tons of lithium concentrate, with the first shipment of 30,000 tons arriving at Yangpu Port in Hainan in January 2026. Additionally, through its subsidiary Roc Oil and the newly acquired oilfield project in Oman, Hainan Mining has accelerated the building of a “minerals + energy” network spanning West Africa, the Middle East, and Southeast Asia.International rating agencies affirm Fosun International’s rating outlook as “stable”Fosun’s financial position remains the market’s primary focus.According to Fosun International’s results announcement, during the Reporting Period, cash, bank balances and term deposits amounted to RMB61.1 billion; unutilized banking facilities amounted to RMB144.6 billion; total debt to total capital ratio was 57%. Fosun has maintained a healthy financial position, with ample cash reserves. International rating agencies have broadly affirmed Fosun International’s rating outlook as “stable”.Guo Guangchang stated in his Letter to Shareholders that, at present, Fosun’s core businesses remain solid, liquidity position is robust, and banking relationships remain stable. The Company’s major shareholder and management team have announced plans to increase their holdings in the shares of the Company and the Company will also proceed with a share buyback program. With Fosun’s core businesses continuing to grow and strategic plans firmly on track, “We are confident in our ability to support a return of the share price to fair value and better protect the long-term interests of our shareholders.”In addition to its results announcement, Fosun announced that it is committed to increasing its dividend payout ratio, targeting an increase from the current 20% to 35% for the 2026 financial year. Based on the accumulated distributable profit of the Company, the dividend for the 2026 financial year is expected to be not less than HKD1.5 billion.We can reasonably expect that this round of “strategic streamlining” will inject greater certainty into Fosun’s future business growth.In this year’s Letter to Shareholders, Guo Guangchang also disclosed Fosun’s medium-term financial goals: “We strive to gradually restore annual profit to the RMB10 billion level; at the group level, we aim to generate RMB60 billion in cash returns, reduce total debt to below RMB60 billion, and strive to achieve an investment-grade rating.” He stated that, “Fosun has always stayed true to its original aspiration: to do the right things, the difficult things and the things that take time to develop. For Fosun’s future, we do not seek short-term gains; we seek to build a foundation for lasting success.” Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - Bringing artificial intelligence from the laboratory to a broad spectrum of industries—particularly in the B2B market—demands that AI companies overcome a formidable set of challenges: how to precisely match complex, ever-evolving business scenarios; how to achieve scalable delivery; and how to establish a sustainable business model.Extreme Vision, based in Qingdao, Shandong, has delivered its answer through a compelling set of metrics. As of September 30, 2025, the Company had completed over 6,000 projects, recorded a product repurchase rate exceeding 80%, and served more than 100 industries, including manufacturing, energy, retail, and transportation. Revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate of 59.2%. The Company turned profitable in 2024.A Platform-based Approach to Tackling the Fragmentation ChallengeExtreme Vision was founded by three entrepreneurs born in the 1990s: Mr. Chan Chan Kit, Ms. Luo Yun, and Mr. Chen Shuo. Mr. Chan Chan Kit holds a direct stake of 16.05% in the Company and serves as its largest shareholder, legal representative, chairman of the board, executive director, and general manager. The three founders, all alumni of Sun Yat-sen University, first conceived the idea of starting a business during their undergraduate studies.“The biggest challenge in the B2B market is fragmentation,” Mr. Chan once noted. Different industries, different enterprises, and even different production processes within the same company all have vastly different AI requirements. If each scenario requires developing algorithms from scratch, the cost is prohibitive, the timeline is protracted, and scaling becomes virtually impossible. This is precisely the “B2B chasm” that many AI companies struggle to cross. Based on this insight, Extreme Vision pioneered the AI Vision Algorithm Marketplace.As of September 30, 2025, Extreme Vision’s algorithm marketplace has launched 1,517 algorithms, including 1,369 algorithms co-developed with third-party developers. Covering application scenarios in over 100 industries, the platform has served more than 3,000 customers and delivered over 6,000 projects since its establishment. Notably, the product repurchase rate has exceeded 80%, reflecting the strong standardization of its solutions and robust market recognition.Self-developed AI infrastructure empowers efficient implementation. The Company’s self-developed AI infrastructure enables efficient algorithm development and rapid solution development. On the one hand, leveraging its self-developed full-stack technology platform, Extreme Vision has built an industry-leading AI infrastructure that covers the entire lifecycle, including data annotation, model training, algorithm development, algorithm testing and inference deployment. On the other hand, the integrated tool engines within its AI development infrastructure significantly lowering the barriers to algorithm development and drastically reducing the time required for customized algorithm development.Multi-industry Implementation: Project Practice as a Driver for Healthy GrowthLeveraging its platform-based capabilities, Extreme Vision has applied its technology to real-world business scenarios across various sectors, delivering actionable and reusable solutions.In terms of industrial manufacturing, Extreme Vision deployed an EHS+AI intelligent monitoring system for CR Beer. By implementing 25 categories of risk-identification algorithms, the system accurately captures risk scenarios such as the improper wearing of safety ropes and goggles, hoisting operations, and unauthorized personnel intrusion during equipment operation. This has successfully transformed traditional passive safety management into proactive, real-time, and automated risk control.In terms of environmental and energy sectors, Extreme Vision has built an intelligent security management platform, “Halo Guard” for China Everbright Environmental Energy. Equipped with nearly 30 AI vision algorithms for safety management and control, the platform conducts real-time monitoring of high-risk operational scenarios such as unloading platforms and burning zones, significantly enhancing operational safety.In the higher education sector, Extreme Vision has jointly established the “Artificial Intelligence Comprehensive Practice Center” with the School of Smart City at Beijing Union University. Leveraging its Extreme Flow platform, the Company supports algorithm teaching and research in universities, helping to cultivate AI talent.In the transportation and mobility sector, Extreme Vision has identified new application scenarios for large model solutions. Using large model technologies, the Company has generated autonomous driving simulation scenario data and conducted hallucination detection for a leading automotive retailer, helping the client reduce reliance on real-world road data collection and optimize the R&D process.These projects not only demonstrate the breadth and depth of Extreme Vision's technology implementation but also collectively underpin the Company's sustained growth. Each successfully delivered project generates experience and reusable modules for future projects, creating a virtuous cycle that contributes to a product repurchase rate of over 80%.Profitability Continuously Validated, Large Model Emerges as a New Growth DriverAs its commercial value continues to be validated, Extreme Vision's profitability has also shown strong growth momentum. The Company's revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate (CAGR) of 59.2%. The gross profit margin improved from 30.6% in 2022 to 40.2% in 2024. The Company recorded a profit of RMB8.71 million in 2024, making it one of the few profitable AI vision companies in China. For the nine months ended September 30, 2025, the Company achieved revenue of RMB136.3 million, a year-on-year increase of 71.7%, with the gross profit margin further rising to 44.9%.Notably, the large model solutions launched by the Company in 2024 contributed RMB62.12 million in revenue, accounting for 24.1% of total revenue. This has become a new growth driver and is expected to unlock further market opportunities.In terms of R&D investment, the Company continued to increase its efforts. R&D expenditure reached RMB44.82 million in 2024, an increase of 22.6% compared to 2023. As of September 30, 2025, the Company had a professional team of 101 R&D personnel. According to the Prospectus, the Company intends to use approximately 60.0% of the net proceeds from the IPO (HK$260.6 million) to enhance R&D capabilities, including the construction of large models and AI infrastructure, as well as the upgrade of AI-PaaS middleware.Broad Market Prospects: The Platform Flywheel AcceleratesIndustry prospects are promising. According to Frost & Sullivan, the market size of China’s emerging enterprise-level computer vision solutions is projected to grow from RMB11.1 billion in 2024 to RMB97.0 billion in 2029, representing a CAGR of 54.3%. This represents an almost eightfold increase in market size over the next five years, indicating strong inherent growth potential in the sector.As large models gain traction globally, market expectations for AI have been further elevated. However, in the B2B market, no matter how cutting-edge the technology is, it must ultimately return to the simple logic of “usability, practicality, and cost controllability.” Extreme Vision's experience shows that a competitive edge for AI companies lies not only in technological leadership but also in the ability to develop standardized solutions for complex industrial scenarios and scale them through platforms and ecosystems.From algorithms to applications, from project delivery to customer retention, Extreme Vision has remained committed to its mission of pushing technological boundaries and harnessing technology for good—building an AI flywheel that continuously generates commercial value. As AI technology permeates all industries, from industrial safety and energy inspection to retail operations, the demand for fragmented long-tail scenarios continues to emerge, positioning Extreme Vision for accelerated growth. However, whether it can continuously increase market share and improve cash flow amid fierce competition remains a core challenge post-listing. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.Return to Profitability Driven by Vaccine Portfolio GrowthAccording to its annual results, CanSinoBIO achieved total revenue of approximately RMB 1.068 billion, representing a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.9 million, marking a return to profitability.The turnaround reflects more than a cyclical rebound and suggests the company is building a more sustainable revenue base through the commercialization of routine vaccines. This has strengthened its ability to generate consistent cash flow.The improvement was driven primarily by organic growth in core operations rather than one-off factors. During the reporting period, the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (trade name: Menhycia(R)) maintained steady revenue growth, while its 13-valent Pneumococcal Conjugate Vaccine (trade name: iPneucia(R)) gained market traction following its launch. A more balanced revenue mix has improved earnings visibility.In addition, CanSinoBIO received multiple government grants and international R&D funding support during the year, reflecting recognition of its technological capabilities and innovative value.Core Products Set to Scale Up, Pipeline Supports Future GrowthBeyond near-term earnings, the company is supported by a diversified pipeline that provides both mid- and long-term growth drivers.As a core growth driver for CanSinoBIO, Menhycia(R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to expand its market reach. In February 2026, the company announced that the supplemental application to expand the age range of applicable population of Menhycia(R) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved, further broadening its target population.Meanwhile, iPneucia(R)—China’s first 13-valent pneumococcal conjugate vaccine using a dual-carrier system (CRM197 and tetanus toxoid)—is expected to generate commercial synergies with Menhycia(R). Shared distribution and marketing channels could help lower marginal sales costs and improve overall efficiency.In addition, the company’s mid-term pipeline remains robust. It’s absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the “DTcP”) for infants (below 2 years old) (the “DTcP Infant”)has been included in the priority review pathway, which will accelerate its approval timeline.To date, no component-based DTaP vaccine developed by domestic manufacturers has been approved for market launch in China. The infant DTcP vaccine is formulated with individually purified pertussis antigens in defined ratios to ensure consistent quality and stability. Its development also lays the groundwork for adolescent and adult component Tdap vaccines and combination vaccines, enhancing the Company’s product portfolio and core competitiveness.From near-term delivery to mid-term development and long-term innovation, CanSino Biologics’ value goes beyond its existing productsR&D Capabilities Support Long-Term CompetitivenessAs a leading innovative vaccine company, CanSinoBIO consistently adheres to a long-term strategy, ensuring the company remains at the forefront of technological exploration and laying a solid foundation for its sustained competitiveness.Its core talent team brings an average of more than 25 years of industry experience across global pharmaceutical and biotechnology companies, spanning research, manufacturing and commercialization. This has enabled the company to establish an integrated development system aligned with international standards and covering the full development cycle from early-stage research to commercialization.Over time, CanSinoBIO has also built five core technology platforms, including viral vector vaccines, synthetic vaccines, protein structure design and Virus-Like Particle (VLP) assembly, mRNA vaccines, and formulation and delivery technologies. These platforms support a diversified innovation system and provide a solid foundation for lifecycle vaccine development.The company continues to focus on differentiated innovation, including multivalent combination vaccines and novel delivery technologies, with the aim of developing globally competitive vaccine products.These technological capabilities have supported the launch of products like Menhycia(R) and iPneucia(R), reinforcing the company’s position in the vaccine sector.International Expansion Gains MomentumMeanwhile, amid intensifying competition in the domestic vaccine market, CanSinoBIO is accelerating its international expansion.Recently, the company announced that its manufacturing facility has passed the PIC/S GMP certification issued by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). PIC/S is an internationally recognized framework for pharmaceutical inspection and certification, comprising regulatory agencies from over 50 countries. This certification not only confirms that Menhycia(R) and iPneucia(R) meet international-quality standards but also enhances the company’s prospects for entering additional global markets.In fact, the Company’s international presence is well established, with Menhycia(R) obtaining Indonesian registration and Halal certification since 2024.The company has also entered into multiple strategic partnerships abroad, covering commercialization, joint R&D, clinical trials, and localized production. Through a “technology transfer + local manufacturing” approach, CanSinoBIO is expanding its presence beyond product exports toward broader technology-based collaboration.Growth Catalysts Point to Potential Re-RatingOverall, the latest results suggest CanSinoBIO is moving through an inflection point, supported by clearer commercialization pathways.Yet, its current market valuation may not fully reflect its investment potential. Looking ahead, potential growth drivers include the expanded indication for Menhycia(R), continued ramp-up in iPneucia(R) sales, the infant DTcP vaccine currently under priority review, as well as further international market expansion. At the same time, China’s policy support for biopharmaceuticals as a strategic sector could provide a favorable backdrop for valuation.As earnings continue to improve and market expectations adjust, the company may see both earnings growth and a re-rating in valuation multiples. Against the backdrop of China’s rising focus on biopharmaceutical innovation, CanSinoBIO’s long-term investment case is increasingly difficult to ignore. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com